KLRS – kalaris therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates
Kalaris Therapeutics (NASDAQ:KLRS) is now covered by analysts at Citizens Jmp. They set a "mkt outperform" rating and a $20.00 price target on the stock.
Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer
Kalaris Therapeutics (NASDAQ:KLRS) is now covered by analysts at Citigroup Inc.. They set an "outperform" rating on the stock.
Kalaris to Present at Stifel 2025 Annual Healthcare Conference
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.